CELG : Summary for Celgene Corporation - Yahoo Finance

U.S. Markets closed

Celgene Corporation (CELG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
122.26-1.01 (-0.82%)
At close: 4:00PM EDT
People also watch
GILDBIIBREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close123.27
Open123.55
Bid122.16 x 200
Ask123.00 x 600
Day's Range121.71 - 123.70
52 Week Range94.42 - 127.64
Volume2,591,313
Avg. Volume3,712,512
Market Cap95.11B
Beta1.53
PE Ratio (TTM)49.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Top Stocks to Buy With Your Tax Refund
    Motley Foolyesterday

    3 Top Stocks to Buy With Your Tax Refund

    Did you just get a refund check from Uncle Sam? Here are three stocks you should consider buying with those funds.

  • Street Watches To See If $125,000 Drug Boosts Biogen's Results
    Investor's Business Daily2 days ago

    Street Watches To See If $125,000 Drug Boosts Biogen's Results

    Wall Street will be keyed in Tuesday to Biogen's earnings for a first look at whether payer pushback hindered sales of Spinraza.

  • American City Business Journals2 days ago

    Celgene research leader Dr. Rupert Vessey joins Juno board

    Juno Therapeutics Inc. has added Celgene Corp. President of Research and Early Development Dr. Rupert Vessey to the Seattle-based biotech's board. Vessey will serve as as Celgene's designated appointee to Juno's board, replacing Dr. Tom Daniel, who retired last summer but will remain on the board as an independent contractor. Juno (JUNO) inked a $1 billion collaboration with Celegene in 2015.